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Objectives.Magnetic resonance imaging (MRI) and in particular diffusion-weighted imaging (DWI) have been broadly proven to
be the reference imaging method to discriminate between cholesteatoma and noncholesteatomatous middle ear lesions, especially
when high tissue specificity is required. The aim of this study is to define a range of apparent diffusion coefficient (ADC) values
within which the diagnosis of cholesteatoma is almost certain. Methods. The study was retrospectively conducted on a cohort
of 124 patients. All patients underwent first- or second-look surgery because primary or secondary acquired cholesteatoma was
clinically suspected; they all had preoperative MRI examination 15 days before surgery, including DWI from which the ADCmaps
were calculated. Results. Average ADC value for cholesteatomas was 859,4 × 10−6 mm2/s (range 1545 × 10−6 mm2/s; IQR = 362 ×
10−6 mm2/s;𝜎= 276,3× 10−6 mm2/s), while for noncholesteatomatous inflammatory lesions, it was 2216,3× 10−6 mm2/s (range 1015×
10−6 mm2/s; IQR = 372,75 × 10−6 mm2/s; 𝜎 = 225,6 × 10−6 mm2/s). Interobserver agreement with Fleiss’ Kappa statistics was 0,96. No
overlap between two groups’ range of values was found and the difference was statistically significant for 𝑝 < 0.0001. Conclusions.
We propose an interval of ADC values that should represent an appropriate benchmark range for a correct differentiation between
cholesteatoma and granulation tissue or fibrosis of noncholesteatomatous inflammatory lesions.
1. Introduction
Middle ear cholesteatoma is an enlarging cystic keratin-filled
mass surrounded by stratified squamous epithelium often
originating from Prussak space or more generally in epitym-
panum. The most common classification of cholesteatomas
is based on pathogenesis, and it differentiates three types
of lesion: congenital (2%), primary acquired (80%), and
secondary acquired (18%) [1]. Although cholesteatoma is
a benignant nonneoplastic lesion, its intrinsic tendency
to erode adjacent bony structures and damage anatomical
components within the temporal bone makes it locally
aggressive and potentially fatal [2]. The diagnosis is mainly
performed by physical examination, based on the presence
of painless otorrhea, hearing loss, and dizziness; occasionally,
first clinical presentation can include symptoms of central
nervous system (CNS) complications, potential confounding
about the origin of the lesion [3–5].
High resolution computed tomography (HRCT) fre-
quently is the first step in the diagnostic imaging assessment
of suspected cholesteatoma because of optimal spatial reso-
lution and high sensitivity for bony erosions; at present, CT
is considered a key element in presurgical planning, helpful
in depicting precise disease extension [2, 6]. Nevertheless,
HRCT is inaccurate for characterizing different types of
effusions that can determine middle ear opacification [2, 3].
When high tissue specificity and sensitivity are required,
especially when postoperative residual or recurrent disease is
suspected [7], it is necessary to resort to magnetic resonance
imaging (MRI), already widely used in assessment of ear
malformations and hearing loss, temporal bone tumors, or
middle ear infections [8–11]. Among different advanced tech-
niques [12], diffusion-weighted imaging (DWI) sequences are
the reference method for neuroradiologists to discriminate
between middle ear cholesteatoma and noncholesteatoma-
tous lesions [13–18]. On DWI, cholesteatoma is hyperintense
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Table 1: Demographical and surgical information of patients
included in the MRI analysis.
Primary
cholesteatoma
(𝑁 = 54)
Secondary
cholesteatoma
(𝑁 = 46)
Age (mean ± SD) 35.43 ± 17.97 36.86 ± 18.35
Sex (M/F) 24/30 10/36
Side (DX/SN) 37/17 16/30
Histology (+/−) 42/12 28/18
in part because of restricted water diffusion, in part because
its content of keratin produces high signal intensity in
the pathological area (T2-shine-through effect), as shown
calculating apparent diffusion coefficient (ADC) values [13].
Among different types of DWI sequences, it has been proved
that the best diagnostic accuracy is obtained with non-
echo-planar (non-EPI) DWI compared to echo-planar (EPI)
techniques [3, 19–21], specifically with multi-shot (Msh) EPI
compared to single-shot (Ssh) non-EPI [22], in particular
after first-time surgery [23–25]. Therefore, the highest reli-
ability for the detection of middle ear cholesteatoma is at
present obtained with MSH-TSE DWI [26]. For diagnostic
purposes, it is necessary to confirm the data obtained by
calculating ADC values from DWI sequences performed
[23]. The aim of this study is to define a range of ADC
values within which the diagnosis of cholesteatoma is almost
certain.
2. Material and Methods
2.1. Patients. FromApril 2011 toMarch 2016, we recruited 124
consecutive unrelated patients (69 females; 55 males; mean
age 35,5 Y) with clinical suspicion of unilateral or bilateral
middle ear cholesteatoma, candidate to surgical procedure.
We included both primary and secondary acquired sus-
pected lesions. In our sample no congenital cholesteatoma
was present. All patients underwent preoperative MRI 15
days before first- or second-look surgery. The diagnosis of
cholesteatoma was always confirmed histologically. Overall,
15 patients were unable to complete MRI examination,
while 9 additional patients were excluded because of their
refusal to undergo surgery. Finally, from the original sam-
ple, 100 patients (56 females; 44 males; mean age 34,9 Y)
were recruited. Demographic and clinical information of all
patients included in the study is shown in Table 1 (Table 1).
The protocol was approved by local Ethical Committee and
written informed consent was preliminarily obtained from all
patients.
2.2. Imaging Technique and Evaluation. MRI was performed
at 1.5 T MR unit (Philips Intera, Philips Medical Systems,
Netherlands) with an 8-channel head coil. The imaging
protocol consisted in TSE T2w on the axial plane (11 slides;
TR 3000ms; TE 120ms; thickness 3.00mm; FA 90; phase I
> S; view size 2338 × 1228; matrix 288 × 288; 6 averages);
T1w SE on three orthogonal axes before and after intravenous
administration of contrast media (11 slides/plane; TR 550ms;
TE 15ms; thickness 3.00mm; FA 90; view size 2338 × 1228;
matrix 256 × 256; 3 averages); T2 3D DRIVE on the axial
plane for the study of inner ear and cerebellopontine angle
(50 slides; TR 1500ms; TE 250ms; thickness 1.40mm; FA
90; phase I > S; view size 2338 × 1228; matrix 320 × 320;
6 averages); coronal multi-shot non-echo-planar diffusion-
weighted imaging (MSH non-EPI DWI). DWI acquisition
was performed on the coronal plane (20 slides; TR 3000ms;
TE 82,44ms; thickness 3.00mm; FA 90; phase R > L; view
size 2338 × 1228; matrix 128 × 128; 𝑏 = 0 and 𝑏 =
800 s/mm2; 5 averages); duringMsh-TSEDWI, cardiac gating
was performed in order to limit patient-related artefacts due
to heart pulse and blood flow. ADC maps were obtained
by using the free Osirix plugin “ADC Map Calculation.”
For each patient, three different neuroradiologists measured
ADC values separately. A circular region of interest (ROI)
of 1mm in diameter was placed in the area where abnormal
restricted diffusion was more evident on DWI sequence with
the highest 𝑏-values (𝑏 = 800) by every single observer and
then automatically transferred to the coregistered ADCmap,
as shown in Figure 1 (Figure 1); the average value of ADC
within the ROI was considered.
2.3. Statistical Analysis. For final analysis, we considered the
arithmetic mean of measured ADC values obtained by the
three neuroradiologists. Considering the normal distribu-
tion of the collected data assessed by using the Shapiro-
Wilk Test for normality, parametric statistical analysis was
performedwith Student’s 𝑡-test (MEDCALC Statistical Soft-
ware). We compared the average ADC values of histolog-
ically confirmed cases of cholesteatoma with the ones of
histologically identified noncholesteatomatous inflammatory
lesions.
3. Results
In 72 cases (Group 1; ch+) primary or secondary acquired
cholesteatoma was confirmed histologically, while in 28 cases
(Group 2; ch−) postoperative findings indicated the presence
of noncholesteatomatous inflammatory tissue. Overall agree-
ment among raters calculated using Fleiss’ Kappa statistics
was 0,96 (Free Marginal Kappa = 0,93). Average ADC value
for cholesteatomas was 859,4 × 10−6 mm2/s (lowest value 𝑄
0
= 477 × 10−6 mm2/s; highest value 𝑄
4
= 2022 × 10−6 mm2/s;
range 1545 × 10−6 mm2/s; IQR = 362 × 10−6 mm2/s; standard
deviation 𝜎 = 276,3 × 10−6 mm2/s). Average ADC value for
noncholesteatomatous inflammatory lesions was 2216,3 ×
10−6 mm2/s (lowest value 𝑄
0
= 1741 × 10−6 mm2/s; highest
value 𝑄
4
= 2756 × 10−6 mm2/s; range 1015 × 10−6 mm2/s;
IQR = 372,75 × 10−6 mm2/s; standard deviation 𝜎 = 225,6 ×
10−6 mm2/s). No overlapping value between the two groups
was found; two outlier values (below 𝑄
1
− 1.5 × IQR or above
𝑄
3
+ 1.5 × IQR) were identified, both in the group of patient
with histologically confirmed cholesteatoma and candidate
to second-look surgery (Figure 2). The difference between
the two groups was statistically significant for 𝑝 < 0.0001.
No significant difference was found between ADC values in
primary and secondary cholesteatoma.
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Figure 1: ((a)-(b))MSH-TSEDWI of a group 1 patient (ch+), with the calculated ADC value on ADC cartography (881 × 10−6 mm2/s); (c)-(d)
MSH-TSE DWI of a group 2 patient (ch−), with the calculated ADC value on ADC cartography (2121 × 10−6 mm2/s).
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Figure 2: Boxplots representing ADC values distribution in group
1 (patients with histologically confirmed cholesteatoma) and group
2 (histologically identified noncholesteatomatous inflammatory
lesions).
4. Discussion
To our knowledge, this report is the first quantitative assess-
ment of a specific range of ADC values for differentiating
between middle ear cholesteatoma and noncholesteatoma-
tous tissue on a relatively large number of patients.
Reproducibility and reliability of ADC values in the
head and neck region of healthy subjects have been recently
assessed, and the importance of MR imaging systems and
sequences performed has been pointed out [27]. With this
knowledge, we tried to systematically investigate accuracy
and reliability of ADC range values in determining whether
middle ear lesions should be attributed to cholesteatoma
with a 1.5 T magnetic resonance field, widely used in clinical
practice and appropriate to diagnostic purposes, as previously
demonstrated [28].
Previous consensus conferences proposed standardized
criteria for ROI placement in diagnosis and response assess-
ment of expansive and tumoral lesions [29], suggesting that
tumor ROI definition should be done on traditional high-
contrast images (i.e., T2-weighted) and then transferred to
the DWI data set. Considering the nonneoplastic nature of
cholesteatoma, in this study, we opted for a small hand-drawn
ROI as commonly used in clinical daily practice. The choice
of ROI size (circular, 1mm in diameter), even if potentially
prone to errors, is prompted by the effort to identify even
small cholesteatomas (≈3mm in diameter). The rationale
behind this option is to exclude from the evaluation tissue
and/or anatomical structures surrounding the suspected
cholesteatoma. Indeed, even if not representing the whole
lesion, a very small ROI may help to discriminate the portion
of residual or recurrent cholesteatoma from granulation and
inflammatory tissue all around; this is particularly important
in case of large recurrent lesions with small inner areas of
restricted water diffusion on DWI.
As the hyperintensity of cholesteatoma on DWI is a
combination of T2 shine-through effect and restricted water
diffusion, to confirm the diagnostic suspicion it is always
4 BioMed Research International
desirable to compare the DWI image to the ADC maps
[23]. In case of true restricted diffusion, as happens with
cholesteatoma, the area of increased DWI intensity will
coincide with the low signal area on ADC map [13, 30]. This
appearance onDWI and on relative ADCmapmakes it possi-
ble to distinguish cholesteatoma from noncholesteatomatous
inflammatory lesions, especially in case of doubt before
second-look surgery [1, 24, 25, 31]. In addition to these
considerations, it is widely recognized that quantitative ADC
measurements are able to improve specificity compared to
the DWI subjective qualitative assessment [32]. Indeed, ADC
helps to identify false positive cases inwhich themisdiagnosis
of cholesteatoma is due to the presence of confounding
factors, including cerumen, haemorrhage following recent
surgery, middle ear packing materials, autologous and het-
erologous bone replacementmaterials, or infections [3, 19, 23,
33].
In the light of previously described results on smaller
samples of patients [13, 30, 32, 34], we found two different
groups of values not overlapping one another: patients with
cholesteatoma were found to have lower ADC values (Group
1; ch+ median 822 × 10−6 mm2/s) compared to patients with-
out cholesteatoma (Group 2; ch−median 2233 × 10−6 mm2/s)
(Figure 2). The difference in intensity signal is mainly due to
the significant amount of granulation tissue and/or fibrosis
of noncholesteatomatous inflammatory lesions. Two outlier
values (below 𝑄
1
− 1.5 × IQR or above 𝑄
3
+ 1.5 × IQR) were
identified in the group of patient candidate to second-look
surgery and with histologically confirmed cholesteatoma.
In both cases, these findings are probably attributable to a
small residual/recurrent cholesteatoma surrounded by a large
amount of granulation tissue. In fact, DWI andADCability to
detect small cholesteatomas is limited to lesions bigger than
2-3mm [35]; therefore, small residual/recurrent pearls within
granulation tissue resulting from first-time surgery can be
easily missed.
Given the sufficiently large sample of this study and
the distribution of the collected data, we propose a bench-
mark interval of ADC for both cholesteatoma and nonc-
holesteatomatous inflammatory lesions ranging from ADC
±1,96 standard deviation 𝜎 (confidence interval 95%). For
cholesteatoma, after excluding the two above-mentioned out-
liers, we suggest a reference range between 318 × 10−6 mm2/s
and 1265 × 10−6 mm2/s, while for noncholesteatomatous
inflammatory lesions we suggest a reference range between
1774 × 10−6 mm2/s and 2658 × 10−6 mm2/s (Figure 3).
No significant difference was found stratifying patients
by primary and secondary acquired cholesteatoma or by age
and sex. For second-look surgery, neither autologous nor
heterologous materials have been used in middle ear surgical
repair in our sample, in order to prevent scan artefacts that
could potentially affect the interpretation of the ADC map
in secondary lesions. A further core strength of this work is
the large number of highly selected patients recruited over
the years compared to the small sample size of previous
studies [30, 32, 34], which did not allow to generalize the
obtained results and to identify specific ranges of values.
An extensive comparison between studies regarding ADC
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Figure 3: Proposed ADC ranges (mean ADC value ± 1,96 standard
deviation 𝜎 → confidence interval 95%). (1) Reference range for
cholesteatoma: 318 × 10−6 mm2/s–1265 × 10−6 mm2/s. (2) Refer-
ence range for noncholesteatomatous inflammatory lesions: 1774 ×
10−6 mm2/s–2658 × 10−6 mm2/s.
values in suspected middle ear cholesteatoma assessment is
presented in Supplementary Table 1. Homogeneous sample
characteristics can be considered both a strength but also a
possible detriment, becausewe did not include any other kind
of lesion with potentially overlapping ADC values. In fact, on
the other hand, the main limitation is the absence of middle
ear abscesses, whose ADC values should have represented
an additional range to the ones described in the study [34].
Moreover, our results related to the MR unit and the specific
DWI sequences used, so their validity in different conditions
should be confirmed by further studies, being ADC values
reproducibility potentially influenced by coil system, specific
sequence performed, andfield strength [27]. Lastly, subjective
placement of a small ROI within the lesions on higher 𝑏-
values DW images can be prone to error because of T2-shine-
through effect, occasionally affecting the goodness of final
result.
5. Conclusions
In conclusion, ADC maps could be helpful in differenti-
ating cholesteatoma from noncholesteatomatous inflamma-
tory lesions, in particular when postoperative residual or
recurrent disease is suspected and differential diagnosis is
difficult to perform. We suggest a reference range between
318 × 10−6 mm2/s and 1265 × 10−6 mm2/s for cholesteatoma
and between 1774 × 10−6 mm2/s and 2658 × 10−6 mm2/s for
noncholesteatomatous lesions.The proposed interval of ADC
values should represent an appropriate benchmark range for
a correct and unambiguous interpretation of what is observed
in non-EPI DWI sequences.
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